Skip to main content
    G

    Gain Therapeutics Inc (GANX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.94
    -0.10 (-9.60%)

    Market Cap: $46.31M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Gain Therapeutics Inc (GANX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Gain Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$20.16M, operating cash flow was -$18.47M and free cash flow was -$18.47M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$3.16M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $18.71M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$55.18K-60.6%100.0%-40328.3%-40354.3%
    Dec 2022$140.11K-15.1%100.0%-12688.1%-12555.1%
    Dec 2021$164.99K+471.3%100.0%-8379.8%-8418.9%
    Dec 2020$28.88K-30.1%100.0%-12047.5%-12387.7%
    Dec 2019$41.30K+100.4%100.0%-5084.9%-5310.9%
    Dec 2018$20.61KN/A100.0%-4989.7%-5364.4%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$0$0$55.18K$140.11K$164.99K$28.88K$41.30K$20.61K
    Gross profit$0$0$55.18K$140.11K$164.99K$28.88K$41.30K$20.61K
    Research and development$10.21M$10.79M$11.52M$8.38M$7.16M$2.26M$1.59M$826.88K
    Operating income-$18.71M-$20.35M-$22.25M-$17.78M-$13.83M-$3.48M-$2.10M-$1.03M
    Net income-$20.16M-$20.41M-$22.27M-$17.59M-$13.89M-$3.58M-$2.19M-$1.11M
    EBITDAN/A-$20.15MN/AN/AN/AN/A-$2.10M-$1.03M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$82.24K$0$0$0$64.80K
    Gross profit$0$0$0$4.87M$0$0$0-$21.31K$0$0$0-$23.59K
    Operating income-$3.20M-$4.68M-$5.35M-$4.47M-$4.79M-$5.09M-$4.37M-$3.33M-$4.46M-$8.18M-$4.38M-$4.41M
    Net income-$3.16M-$4.68M-$5.61M-$4.54M-$5.28M-$5.81M-$4.53M-$3.77M-$4.49M-$8.14M-$4.01M-$4.72M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $400.95K by $20.44M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$22.82M$12.12M$18.61M$24.10M$38.99M$9.60M$660.29K$811.63K
    Current assets$22.24M$11.60M$17.78M$21.09M$37.72M$8.99M$398.05K$494.64K
    Cash and equivalents$20.84M$10.39M$11.79M$7.31M$36.88M$7.49M$303.32K$400.69K
    Total liabilities$4.25M$4.78M$6.03M$5.22M$4.17M$3.40M$1.11M$1.76M
    Short-term debt$100.87K$110.18K$118.80K$108.14K$103.83K$22.63K$102.11K$97.59K
    Long-term debt$300.08K$328.33K$449.05K$495.26K$590.47K$715.66KN/AN/A
    Shareholder equity$18.56M$7.34M$12.58M$18.88M$34.82M$6.20M-$449.86K-$950.91K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$13.23M$15.42M$18.74M$22.82M$10.97M$9.83M$11.62M$12.12M$14.37M$19.20M$14.58M$18.61M
    Total liabilities$3.08M$4.13M$4.73M$4.25M$5.06M$6.14M$5.84M$4.78M$5.46M$7.41M$5.94M$6.03M
    Cash and equivalents$11.70M$13.08M$16.54M$20.84M$8.81M$6.69M$9.07M$10.39M$12.05M$16.94M$10.64M$11.79M
    Shareholder equity$10.15M$11.29M$14.01M$18.56M$5.91M$3.70M$5.78M$7.34M$8.91M$11.78M$8.64M$12.58M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$18.47M-$18.87M-$18.87M-$14.69M-$12.37M-$3.24M-$1.87M-$744.51K
    Capital expenditures$0$22.49K$15.36K$118.95K$94.21K$20.83K$13.72K$7.99K
    Free cash flow-$18.47M-$18.90M-$18.88M-$14.81M-$12.46M-$3.26M-$1.88M-$752.50K
    Share repurchases$395.48K$280.87K$0N/A$853.49K$470.75KN/AN/A
    Investing cash flow$0$4.98M$10.22M-$14.77M-$94.21K-$20.83K-$13.72K-$7.99K
    Financing cash flow$28.45M$13.01M$12.64M-$78.77K$41.77M$10.49M$1.75M$983.78K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.05M-$4.68M-$4.73M-$4.62M-$4.93M-$5.10M-$3.82M-$3.45M-$6.08M-$5.76M-$3.59M-$5.66M
    Capital expendituresN/AN/A$3$3$4$2$3$945$1$21.55K$3$19
    Free cash flowN/AN/A-$4.73M-$4.62M-$4.93M-$5.10M-$3.82M-$3.46M-$6.08M-$5.78M-$3.59M-$5.66M
    Last 12 quarters

    Frequently Asked Questions About GANX

    What is Gain Therapeutics' annual revenue?

    Gain Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Gain Therapeutics profitable?

    No. Gain Therapeutics reported net income of -$20.16M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does GANX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$18.47M minus capital expenditures of $0 produced free cash flow of -$18.47M.

    How much debt does Gain Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $300.08K, short-term debt of $100.87K and cash and equivalents of $20.84M.